NEJM· @NEJM · X·· 5 小时前评分70
正文 · 原文
Original Article: Divarasib as Compared with Sotorasib or Adagrasib in 𝘒𝘙𝘈𝘚 G12C–Mutated NSCLC (phase 3 Krascendo 1 trial) https://nej.md/4BiCvbk
#ESMO26 | @myESMO
1307 浏览 · 4 赞 · 2 转发 · 0 回复
会议摘要
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgKRASCENDO-1
https://esmocongress.esmo.orgKRASCENDO-1
https://esmocongress.esmo.org来源：NEJM · x.com